Reykjavik, Iceland, 11 June 2007 -- Actavis Group (OMX: ACT), the international generic pharmaceuticals company, today announced the launch of Finasteride tablets in 14 European countries. The distribution of the product has already commenced. Actavis has already had well over 100 product and market launches this year, and before year end more than 500 launches will be completed. Finasteride was launched as the patent protection expired in the UK, the Netherlands, Germany and Denmark. Actavis currently sells the product under its own label in 12 countries, both in Europe and in the US. Actavis' Third Party division sells the product to a number of its customers in eight countries. Finasteride is a new molecule in Actavis' portfolio this year and is available in tablets of 5mg. It is the generic equivalent of MSD's Proscar® tablets and is used as a treatment in benign prostatic hyperplasia (BPH) and in prostate cancer. Actavis' formulation was developed in Iceland and the bioequivalence study was conducted in South Africa. The production takes place in India. Inquiries Halldór Kristmannsson Vice President of Corporate Communications & IR Tel: (+354) 535 2325 / 840 3425 E-mail: [email protected] About Actavis Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. Based in Iceland, the company has operations in 39 countries, with 11,000 employees. The company's market capitalization is approximately EUR3.3 billion and is listed on the OMX stock exchange in Iceland. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company's single largest market. Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.